4-甲氧基-2,6-二甲基吡啶 | 20815-02-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-甲氧基-2,6-二甲基吡啶
• 英文名称: 4-methoxy-2,6-dimethylpyridine
• 英文别名: 4-methoxy-2,6-lutidine；4-methoxy-2,6-dimethyl-pyridine；4-Methoxy-2,6-dimethyl-pyridin；2,6-Dimethyl-4-methoxy-pyridin
• CAS: 20815-02-5
• 化学式: C₈H₁₁NO
• mdl: MFCD08061319
• 分子量: 137.181
• InChiKey: BCBIEDKMLUJHJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-甲氧基-2,6-二甲基吡啶 在 potassium permanganate 作用下， 以61%的产率得到4-甲氧基-2,6-吡啶二甲酸
  参考文献：
  名称：

  Novel Late Transition Metal Catalysts Based on Iron: Synthesis, Structures and Ethylene Polymerization

  摘要：

  In this article we reported synthesis, characterization and ethylene polymerization behavior of two new late transition metal 2,6-bis(imino)pyridine catalysts based on iron(II) possessing different substituents of NO(2) (catalyst b) and OMe (catalyst c) at the para position of the pyridine ring. Theoretical study exhibited more positive charge on the central metal of the catalyst b, leading to higher activity offset by lower thermal stability and life time.

  DOI：

  10.1007/s10562-010-0433-x
• 作为产物：
  描述：

  2,6-二甲基吡啶 N-氧化物 在 硫酸 、 硝酸 、 三苯基膦 作用下， 以 甲醇 、 三乙二醇 为溶剂， 反应 13.0h， 生成 4-甲氧基-2,6-二甲基吡啶
  参考文献：
  名称：

  Novel Late Transition Metal Catalysts Based on Iron: Synthesis, Structures and Ethylene Polymerization

  摘要：

  In this article we reported synthesis, characterization and ethylene polymerization behavior of two new late transition metal 2,6-bis(imino)pyridine catalysts based on iron(II) possessing different substituents of NO(2) (catalyst b) and OMe (catalyst c) at the para position of the pyridine ring. Theoretical study exhibited more positive charge on the central metal of the catalyst b, leading to higher activity offset by lower thermal stability and life time.

  DOI：

  10.1007/s10562-010-0433-x

文献信息

• Pyridine compounds and their pharmaceutical use
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06521643B1

  公开（公告）日：2003-02-18

  A compound of formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof possess a strong inhibitory activity on the production of nitric oxide (NO), and are useful for prevention and/or treatment of NOS(nitric oxide synthasey)-mediated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, insulin-ependent diabetes mellitus, ulcerative colitis, cerebral infarction, rheumatoid arthritis, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, pain, ulcer, and the like in human being and animals.

  根据所附的规格说明书，本发明的化合物(I)和药用可接受的盐具有强烈的抑制一氧化氮(NO)生成的活性，并且可用于预防或治疗由NOS（一氧化氮合酶）介导的疾病，例如成人的呼吸窘迫综合征、心肌炎、滑膜炎、败血症休克、胰岛素依赖型糖尿病、溃疡性结肠炎、脑梗塞、类风湿性关节炎、骨关节炎、骨质疏松症、系统性红斑狼疮、器官移植排斥反应、哮喘、疼痛、溃疡等人类和动物的疾病。
• [EN] 7-ARYL-1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE LA 7-ARYL-1,2,4-TRIAZOLO [4,3-A] PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010130423A1

  公开（公告）日：2010-11-18

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型Formula (I)的三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2 ("mGluR2")的阳性变构调节剂，适用于治疗或预防与谷氨酸功能障碍有关的神经和精神疾病，以及mGluR2代谢型受体亚型参与的疾病。本发明还涉及包括这些化合物的药物组合物，用于制备这些化合物和组合物的方法，以及利用这些化合物预防或治疗与mGluR2有关的神经和精神疾病和疾病的用途。
• [EN] PROTEOSTASIS REGULATORS FOR TREATING CYSTIC FIBROSIS AND OTHER PROTEIN MISFOLDING DISEASES<br/>[FR] RÉGULATEURS DE PROTÉOSTASIE POUR LE TRAITEMENT DE LA MUCOVISCIDOSE ET AUTRES MALADIES DE MAUVAIS REPLIEMENT DES PROTÉINES
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2012154880A1

  公开（公告）日：2012-11-15

  The present invention is directed to compounds of Formulae (Ia-Ib), (Ila-IId), (Illa- Illb), (IV), (V), (VI), (Vlla-VIIc), (VIII), (IXa-IXb), (Xa-Xb), (XIa-XIb) and (Xlla-XIIb), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.

  本发明涉及式(Ia-Ib)、(IIa-IId)、(IIIa-IIIb)、(IV)、(V)、(VI)、(VIla-VIIc)、(VIII)、(IXa-IXb)、(Xa-Xb)、(XIa-XIb)和(XIIa-XIIb)的化合物，以及这些化合物的药物组合物和在治疗与蛋白质稳态失调相关的疾病中的使用方法。
• Development of Highly Active Ir–PNP Catalysts for Hydrogenation of Carbon Dioxide with Organic Bases
  作者：Wataru Aoki、Natdanai Wattanavinin、Shuhei Kusumoto、Kyoko Nozaki

  DOI：10.1246/bcsj.20150311

  日期：2016.1.15

  Methoxy-substituted PNP–iridium(III) complexes and pyrazine-based PNP–iridium(III) complexes were developed and used to hydrogenate carbon dioxide in the presence of triethanolamine as a base. The ...

  甲氧基取代的 PNP-铱 (III) 配合物和吡嗪基 PNP-铱 (III) 配合物被开发并用于在三乙醇胺作为碱存在下氢化二氧化碳。这 ...
• <i>cis</i>/<i>trans</i> Isomerization of <i>o</i>-Phosphino-Arenesulfonate Palladium Methyl Complexes
  作者：Xiaoyuan Zhou、Ka-Cheong Lau、Benjamin J. Petro、Richard F. Jordan

  DOI：10.1021/om501007q

  日期：2014.12.22

  −25 °C. Kinetic studies revealed lutidine-catalyzed and noncatalyzed isomerization pathways. The lutidine-catalyzed pathway involves five-coordinate (PO-OMe)PdMe(lut)2 intermediates that undergo Berry pseudorotation. Kinetic studies, structure–activity relationships, solvent effects, and density functional theory calculations for the noncatalyzed pathway are most consistent with a mechanism, originally

  研究了（PO-OMe）PdMe（lut）（[PO-OMe] - = 2- P（2-OMe-Ph）2 } -4-Me-苯磺酸盐）的顺式/反式异构化（邻-膦基-芳烃磺酸盐）PdR（乙烯）物质在乙烯聚合中的链增长反应。的非平衡混合物-P顺，Ç和-反式-对，Ç - （PO-OME）PDME（2,6-二甲基吡啶）中的Na [PO-OME]和的Pd（μ-Cl）的ME的反应生成（2,6-二甲基吡啶）} 2在CD 2 Cl 2中在-25°C下。动力学研究揭示了二甲基吡啶的催化和非催化的异构化途径。二甲基吡啶催化的途径涉及经历Berry假旋转的五配位（PO-OMe）PdMe（lut）2中间体。动力学研究，结构-活性关系，溶剂效应和非催化途径的密度泛函理论计算与最初由Nozaki，Morokuma和他的同事提出的，与κ经历五坐标过渡态的机理最一致。[PO] -配体的3 - P，O，O配位。